News
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Shares of Eli Lilly ( LLY -2.37%) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
2don MSN
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback